New Tool for Assessing Dehydration Is Built for Global Deployment
UF Health researchers teamed up with Brown University and researchers in Bangladesh to create FluidCalc, a tool that utilizes an algorithm to determine a patient’s dehydration and calculates how much fluid they need. This tool is aimed at treating dehydration caused by diarrhea, which kills more than 1 million people each year. Until now, there hasn’t been an easy-to-use tool for assessing dehydration.
Atsena Therapeutics Receives FDA Designation for Treatment of Severe Congenital Eye Disease Using Gene Therapy
Atsena Therapeutics has been granted Regenerative Medicine Advanced Therapy designation from the FDA to continue their research on a cure to Leber congenital amaurosis. Patients with this disease are missing a gene that regulates retinal function and visually-guided behavior, causing blindness at an early age.
Atsena Therapeutics Receives FDA Clearance of an Investigational Gene Therapy for X-Linked Retinoschisis
The U.S. Food and Drug Administration (FDA) has cleared Atsena Therapeutics’ Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.